Why there is a blockage in the biosample system
Dr Robert Hewitt explores why a shift is required in the way that biosamples are sourced by the drug discovery industry, including smaller biotech companies.
List view / Grid view
Dr Robert Hewitt explores why a shift is required in the way that biosamples are sourced by the drug discovery industry, including smaller biotech companies.
Scientists at the New York University (NYU) Abu Dhabi have used nuclear magnetic resonance (NMR) techniques to determine the structure of a specific nanobody, Nb23. Drug Target Review’s Victoria Rees spoke with lead researcher Professor Gennaro Esposito to find out how their findings could lead to a better understanding of…
CRISPR holds great promise in advancing pharmacological research and has fuelled the rapid expansion of using gene-edited cells for drug discovery processes. CRISPR-Cas9 dropout screens have emerged as a useful tool for high-throughput large-scale loss-of-function screens, which seek to identify the relationship between genotype and phenotype. Dr Pushpanathan Muthuirulan, Research…
Synthetic biology processes can be useful to therapeutic development, diagnostics and vaccine advancement. Drug Target Review’s Victoria Rees spoke with Dr Jim Collins, Termeer Professor of Medical Engineering & Science at MIT and Founding Core Faculty & Lead, Living Cellular Devices at the Wyss Institute at Harvard University, to explore…
Despite the rapid deployment of vaccines among global populations, therapeutics such as antibodies are still required. Here, Dr Steve Carroll, Vice President of Pre-clinical Sciences at IGM Biosciences, explains how a potential Immunoglobulin M (IgM) antibody treatment has been developed that shows promise for combatting SARS-CoV-2 and variants of concern in pre‑clinical…
In this article, Dr Jens Bjørheim, Chief Medical Officer of Ultimovacs, explains why vaccination has proved the best strategy to target human telomerase and why this complex may be an effective approach to combat cancer.
Guided by precise biomarker tests, therapeutic vaccines targeting the pathology of neurodegenerative disease could provide solutions to the impending global crisis in dementia. As Dr Andrea Pfeifer, Co-Founder, Chief Executive Officer and Director of AC Immune, describes here, current work is both establishing the targets that those vaccines must address…
In a new study, researchers at Brigham and Women’s Hospital, US, successfully developed stem cell-derived neuronal profiles from individual patients. Here, Drug Target Review’s Victoria Rees explores the findings and how these new models can help to advance precision and personalised medicine.
Sheraz Gul explores how machine learning and artificial intelligence represent an exciting opportunity for the drug discovery industry, with the potential to develop highly optimised small molecules.
CRISPR libraries can be highly useful for target identification, gene screens and drug discovery. Dr Erik Willems, Senior Manager of Cell Biology at Thermo Fisher Scientific, discusses the company’s CRISPR libraries and the advantages they can offer scientists.
Included in this ebook are articles exploring the discovery of therapeutics that can be repurposed against COVID-19 and discussing a novel assay approach for the identification of drug targets using mass spectrometry.
This ebook has features on the development of intranasally-delivered antibodies to combat SARS-CoV-2 and how the structure of a nanobody was determined using nuclear magnetic resonance methods.
In this ebook, discover why CRISPR can aid the development of new drugs via loss-of-function screens and how the field of synthetic biology is likely to evolve within the context of health.
Within this ebook, find articles examining the role of telomerase for universal cancer vaccines and discussing potential targets for neurodegenerative disease vaccines.
In this issue, find articles exploring why CRISPR is useful for high-throughput drug discovery, how targeting telomerase may lead to universal cancer vaccines and a new study to identify therapeutics that can be repurposed against COVID-19. Also included are features on neuroscience, organoids and antibodies.